Allergan, Inc.
http://www.allergan.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Allergan, Inc.
J&J Gets Into The Anti-TSLP Game With Proteologix Buyout
The privately held biotech will bring J&J a pair of bispecific antibodies expected to target multiple pathologic pathways in atopic dermatitis and asthma.
Oncology Reinvents Itself To Retain Position As Biotech Investors’ Darling
Experts from across the biotech ecosystem spoke at a Citeline-sponsored panel at Swiss Biotech Day to discuss how pent-up demand was driving investment in areas outside of oncology, but how there was still room for innovation within the cancer market for those who ask the right questions.
Development Versus Dealmaking: How To Obtain A Blockbuster
Most of the companies with blockbuster drugs approved over the past decade oversaw their clinical development internally. Lilly holds the lead with eight blockbusters developed in-house.
Deals In Bag, Dr Reddy’s Sharpens Top 5 Targeted Home Run
Dr Reddy’s shapes journey to the top 5 league on home turf, backed by a string of deals with big pharma to bridge portfolio gaps and supplement its base business. Can they deliver impactful gains in the competitive Indian market?
Company Information
- Industry
-
Pharmaceuticals
- OTC, Consumer
- Specialty Pharmaceuticals
-
Drug Delivery
- Controlled Release
- Site Specific
-
Medical Devices
- Implantable Devices
- Surgical Equipment & Devices
- Other Names / Subsidiaries
-
- Inamed
- MAP Pharmaceuticals, Inc. (MAPP)
- Oculex Pharmaceuticals, Inc.
- SkinMedica, Inc.
- Vicept
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice